Viewing Study NCT05421104

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:56 PM
Ignite Modification Date: 2026-01-05 @ 7:19 PM
Study NCT ID: NCT05421104
Status: COMPLETED
Last Update Posted: 2022-07-05
First Post: 2022-06-13
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Polycythemia Vera (PV) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Polycythemia vera, View
None Ruxolitinib, View
None JAK protein inhibitor, View
None Hydroxyurea, View
None Thrombotic events View